Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

TracyAnn Perry

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Experimental Neurology|November 28, 2006
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathyTracyAnn Perry, Harold W Holloway, Ananda Weerasuriya, et al.
Journal of Neuroscience Research|May 16, 2003
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and ironTracyAnn Perry, Debomoy K Lahiri, Kumar Sambamurti, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2002
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cellsTracyAnn Perry, Debomoy K Lahiri, Demao Chen, et al.
Annals of the New York Academy of Sciences|February 1, 2005
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonistsNigel H Greig, Mark P Mattson, Tracyann Perry, et al.
Journal of Alzheimer'S Disease : JAD|March 24, 2010
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's diseaseYazhou Li, Kara B Duffy, Mary Ann Ottinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2009
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismYazhou Li, TracyAnn Perry, Mark S Kindy, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Experimental Neurology|November 28, 2006
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathyTracyAnn Perry, Harold W Holloway, Ananda Weerasuriya, et al.
Journal of Neuroscience Research|May 16, 2003
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and ironTracyAnn Perry, Debomoy K Lahiri, Kumar Sambamurti, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2002
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cellsTracyAnn Perry, Debomoy K Lahiri, Demao Chen, et al.
Annals of the New York Academy of Sciences|February 1, 2005
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonistsNigel H Greig, Mark P Mattson, Tracyann Perry, et al.
Journal of Alzheimer'S Disease : JAD|March 24, 2010
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's diseaseYazhou Li, Kara B Duffy, Mary Ann Ottinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2009
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismYazhou Li, TracyAnn Perry, Mark S Kindy, et al.
Pageof 2